Overview

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Phase:
Phase 3
Details
Lead Sponsor:
Rigel Pharmaceuticals
Treatments:
Antibodies
Autoantibodies
Immunoglobulins